guardanthealth.comCrawled Oct 16, 2026
The page describes testing advanced breast cancer patients for ESR1 mutations before disease progression at no added cost.
Guardant Reveal is a tissue-free blood test that monitors ctDNA across the care continuum - from MRD detection to therapy response monitoring
Guardant360 Liquid CDx is an FDA-approved liquid biopsy that delivers genomic and epigenomic insights for comprehensive cancer profiling.
Guardant360 Tissue is the most advanced multiomic tissue biopsy that delivers DNA, RNA, and epigenomic insights. Medicare-covered for all advanced solid tumors.
Guardant provides resources on insurance and Medicare coverage, the myGuardant patient portal, and at-home blood draw services.
The page features news and stories about Guardant Health.
The company provides resources and multimedia assets related to its company and products.
Guardant Health's newsroom features press releases and news coverage and provides contact information for its global communications team.
Guardant Health's page features press releases.
Guardant's leadership team is composed of proven executives passionate about transforming cancer care for patients.
Outdated guidelines are keeping millions of eligible Americans from life-saving blood-based screening options. It’s time for action.
The company's mission is to conquer cancer with data.
The page advocates access to modern cancer screenings and states that the COVID-19 pandemic resulted in more than 9.5 million missed screenings in the United States.
The company's support teams assist with questions and provide access to a Whistleblower Hotline.
Guardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.
Guardant Health uses cookies and tracking technologies; its Cookie Policy explains how they are used.
The policy describes data collected on the company's careers sites, how it may be used, and individuals' rights regarding its use.
The page presents terms and conditions for Guardant Health's data transfer services and terms of use.
GitHubRepository owner
Empirik, a Sequoia-incubated infrastructure startup, spins out independently with $21 million in seed funding from Sequoia, Canapi, and Alumni Ventures to predict outages by tracking system changes and their potential effects across infrastructure. Led by CEO Kartik Chandrayana, it permits low-risk changes, sets guardrails on larger updates, and flags dangerous ones for human review. Its customers include Guardant Health and a major consumer packaged goods company.
Sep 2026TechCrunchNews article
A federal judge orders Guardant Health to pay more than $245 million to TwinStrand Biosciences and the University of Washington over infringement of patents covering Duplex Sequencing. The judgment includes $83.4 million in jury damages, $19.5 million in supplemental damages, $119.4 million in accrued royalties and $22.9 million in interest, and requires a 6% royalty on covered sales through March 2033. Guardant says collection will be stayed pending appeal and plans to challenge the ruling.
Aug 2026GeekWireNews article
